UCL Therapeutic Innovation Networks


High-Content Biology Platform

The High Content Biology Platform lab employ high-throughput screening technologies as a means to identify novel components that modify cellular signal transduction pathways and autophagy

Robin Ketteler High Content Biology Platform lab

13 January 2020

They are developing novel screening technologies based on arrayed CRISPR libraries and using knockout cell panels, where their studies will generate strategies for the identification of potential therapeutic targets in diseases such as cancer and neuro-degeneration. Robin Ketteler's initiative has the resources and expertise to translate these basic research findings into a drug discovery program to identify potential therapeutic lead compounds.

Visit the High Content Biology Platform website